XENETIC BIOSCIENCES, INC. Restricted Cash and Cash Equivalents
XENETIC BIOSCIENCES, INC. (XBIO) had Restricted Cash and Cash Equivalents of $0 as of 2019-09-30, per its 10-Q filed 2019-11-14.
Discontinued › Balance Sheet › Assets
us-gaap:RestrictedCashAndCashEquivalents · last filed 2019-11-14
- 2019-09-30: Restricted Cash and Cash Equivalents $0.00.
- 2019-06-30: Restricted Cash and Cash Equivalents $0.00.
- 2019-03-31: Restricted Cash and Cash Equivalents $66.51K.
- 2018-12-31: Restricted Cash and Cash Equivalents $66.51K.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2019-09-30 | $0.00 10-Q · filed 2019-11-14 |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-14 |
| 2019-03-31 | $66.51K 10-Q · filed 2019-05-13 |
| 2018-12-31 | $66.51K 10-Q · filed 2019-11-14 |
| 2018-09-30 | $66.51K 10-Q · filed 2018-11-09 |
| 2018-06-30 | $66.51K 10-Q · filed 2018-08-10 |
| 2018-03-31 | $66.51K 10-Q · filed 2018-05-15 |
| 2017-12-31 | $66.51K 10-Q · filed 2018-11-09 |
| 2017-09-30 | $66.51K 10-Q · filed 2017-11-14 |
| 2017-06-30 | $66.51K 10-Q · filed 2017-08-14 |
| 2017-03-31 | $66.51K 10-Q · filed 2017-05-15 |
| 2016-12-31 | $66.51K 10-K · filed 2018-03-30 |
| 2016-09-30 | $66.51K 10-Q · filed 2016-11-14 |
| 2016-06-30 | $66.51K 10-Q · filed 2016-08-15 |
| 2016-03-31 | $66.51K 10-Q · filed 2016-05-16 |
| 2015-12-31 | $66.51K 10-K · filed 2017-03-31 |
| 2014-12-31 | $66.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |